Risperidone in the Treatment of Schizotypal Personality Disorder
J Clin Psychiatry 2003;64(6):628-634
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: Schizotypal personality disorder
(SPD) has many phenomenological, genetic, physiologic, and
neuroanatomical commonalities with schizophrenia. Patients with
the disorder often suffer from marked social and occupational
impairment, yet they have been difficult to treat with
medications because of their unusual sensitivity to side effects.
This study was designed to determine whether low-dose risperidone
treatment is acceptable to SPD patients and can reduce
characteristic schizotypal symptoms. In addition, if SPD patients
respond to an antipsychotic medication, this will provide support
for the notion of a commonality in treatment response between SPD
Method: Twenty-five patients with DSM-IV-defined
SPD were entered into a 9-week randomized, double-blind,
placebo-controlled study of low-dose risperidone (starting dose
of 0.25 mg/day, titrated upward to 2 mg/day) in the treatment of
SPD. Patients were rated with the Positive and Negative Syndrome
Scale (PANSS), the Schizotypal Personality Disorder
Questionnaire, the Hamilton Rating Scale for Depression, and the
Clinical Global Impressions scale. Data were collected from 1995
Results: The subjects had a low incidence of
depression and of comorbid borderline personality disorder.
Patients receiving active medication had significantly (p <
.05) lower scores on the PANSS negative and general symptom
scales by week 3 and on the PANSS positive symptom scale by week
7 compared with patients receiving placebo. Side effects were
generally well tolerated, and there was no group difference in
dropout rate for side effects.
Conclusion: Low-dose risperidone appears to be
effective in reducing symptom severity in SPD and is generally